A primer on economic evaluations related to expansion of newborn screening for genetic and metabolic disorders

JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing

Volumn 35, Issue 6, 2006, Pages 692-699

  Hubbard, Heddy Bishop ^a,b  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Costs and outcomes; Decision modeling; Economic evaluations; Genetic and metabolic disorders; Newborn screening

Indexed keywords

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST BENEFIT ANALYSIS; ECONOMICS; FINANCIAL MANAGEMENT; GENETIC DISORDER; GENETIC SCREENING; GOVERNMENT; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; METABOLIC DISORDER; METHODOLOGY; NEWBORN; NEWBORN SCREENING; NURSE ATTITUDE; NURSING; ORGANIZATION; OUTCOME ASSESSMENT; REVIEW; UNITED STATES;

COST-BENEFIT ANALYSIS; DECISION MAKING, ORGANIZATIONAL; FEDERAL GOVERNMENT; FINANCING, GOVERNMENT; GENETIC DISEASES, INBORN; GENETIC SCREENING; HEALTH POLICY; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; INFANT, NEWBORN; METABOLIC DISEASES; NEONATAL SCREENING; NURSE'S ROLE; OUTCOME ASSESSMENT (HEALTH CARE); STATE GOVERNMENT; TECHNOLOGY ASSESSMENT, BIOMEDICAL; UNITED STATES;

EID: 36448962413     PISSN: 08842175     EISSN: 15526909     Source Type: Journal    
DOI: 10.1111/J.1552-6909.2006.00098.x     Document Type: Article

References (38)

1. Acharya, K., Ackerman, P., & Ross, L. (2005). Pediatrician's attitudes toward expanding newborn screening. Pediatrics, 116, 476-484.
2. Adelmanm, C. (1981). The constitutionality of mandatory genetic screening statutes. Case Western Reserve Law Review, 31, 897-948.
3. American Academy of Pediatrics Newborn Screening Task Force. (2000). Serving the family from birth to the medical home. Newborn screening: A blueprint for the future - A call for a national agenda on state newborn screening programs. Pediatrics, 106, 389-422.
4. Andrews, L. B. (1985). State laws and regulations governing newborn screening. Chicago: American Bar Foundation.
5. Association of State and Territorial Health Officials. (2005). Financing state newborn screening systems in an era of change. Rockville, MD: Health Resources and Services Administration.
6. Banta-Wright, S. A., & Steiner, R. D. (2004). Tandem mass spectrometry in newborn screening: A primer for neonatal and perinatal nurses. Journal of Perinatal Neonatal Nursing, 18, 41-58; quiz 59-60.
7. Bender, D. R. (1992). Avoiding the cost burden of newborn screening for the poor and uninsured: Mississippi's model. Journal of health & social policy, 3, 51-58.
8. Berg, A. (2005). USPSTF and EGAPP, genomics and medicine: How do we facilitate clinical translation of gene-based discoveries? Rockville MD: Agency for Health Care Research and Quality.
9. Brosnan, C., Brosnan, P., Therrell, B., Slater, C., Swint, J., Annegers, J., et al. (1998). A comparative cost analysis of newborn screening for classic congenital adrenal hyperplasia in Texas. Public Health Reports, 113, 170-178.
10. Canadian Coordinating Centre for Health Technology Assessment. (1997). Guidelines for economic evaluation of pharmaceuticals. Canada. Int J Technol Assess Health Care, 11, 796-797. Ottawa, Ontario, Canada.
11. Cartwright, W. S. (1999). Methods for the economic evaluation of health care programmes, second edition. By Michael F. Drummond, Bernie O'Brien, Greg L. Stoddart, George W. Torrance. Oxford: Oxford University Press, 1997. Journal of Mental Health Policy and Economics, 2, 43.
12. Chace, D. H., Kalas, T. A., & Naylor, E. W. (2003). Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clinical Chemistry, 49, 1797-1817.
13. Drummond, M., O'Brien, M., Stoddart, G., & Torrance, G. (1997). Methods for the economic evaluation of health care programmes. Oxford, U.K.: Oxford University Press.
14. Fost, N. (2005). Ethical issues in newborn screening: The PKU story, genomics and medicine: How do we facilitate clinical translation of gene-based discoveries? Rockville, MD: Agency for Healthcare Research and Quality.
15. Government Accounting Office (GAO) (2003). Newborn screening: Characteristics of state programs. Report to congressional requesters, Washington, DC: Author.
16. Gold, M., Siegel, J., Russell, L., & Weinstein, M. (1996). Cost-effectiveness in health and medicine. Oxford, U.K.: Oxford University Press.
17. Great Lakes Regional Genetics Group. (1996). Newborn screening: An overview of newborn screening programs in the United States, Canada, Puerto Rico, and the Virgin Islands. Springfield Council of Regional Networks for Genetic Services (CORN); Illinois Department of Public Health. Springfield, II:
18. Grosse, S. D., 2004. Does newborn screening save money? The difference between cost-effective and cost-saving interventions. Journal of Pediatrics, 146, 168-170.
19. Harris, R., Helfand, M., Woolf, S., Lohr, K., Mulrow, C., Teutsch, S., et al. (2001). Current methods of the US Preventive Services Task Force: A review of the process. American Journal of Preventive Medicine, 20(3 Suppl.), 21-35.
20. Insinga, R., Laessig, R., & Hoffman, G. (2002). Newborn screening with tandem mass spectrometry: Examining its cost-effectiveness in the Wisconsin Newborn Screening Panel. Journal of Pediatrics, 141, 524-531.
21. Jones, P. M., & Bennett, M. J. (2002). The changing face of newborn screening: Diagnosis of inborn errors of metabolism by tandem mass spectrometry. International Journal of Clinical Chemistry and Applied Molecular Biology, 324, 121-128.
22. Kolata, G. (2005, February 21). Panel to advise tests on babies for 29 diseases. New York Times, p. 1.
23. Ladhani, S. (2004). The risks and benefits of neonatal screening. British Journal of Midwifery, 12, 24-29.
24. Lloyd-Puryear, M., & Forsman, I. (2002). Newborn screening and genetic testing. Journal of Obstetric, Gynecology and Neonatal Nursing, March-April, 200-207.
25. March of Dimes. (2004). Newborn screening tests. Retrieved June 6, 2005 from marchofdimes.com/professional/580.asp
26. Mauskopf, J. A., Paul, J. E., Grant, D. M., & Stergachis, A. (1998). The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics, 13, 277-288.
27. Newborn Screening Task Force Report. (2000). Serving the family from birth to the medical home. Newborn screening: A blueprint for the future - A call for a national agenda on state newborn screening programs. Pediatrics, 106, 389-422.
28. Pandor, A., Eastham, J., Beverley, C., Chilcott, J., & Paisley, S. (2004). Clinical effectiveness and cost-effectiveness of neonatal screening for inborn errors of metabolism using tandem mass spectrometry: A systematic review. Health Technology Assessment, 8, iii, 1-121.
29. Pollitt, R. J., Green, A., McCabe, C. J., Booth, A., Cooper, N. J., Leonard, J. V., et al. (1997). Neonatal screening for inborn errors of metabolism: Cost, yield and outcome. Health Technology Assessment, 1, i-iv, 1-202.
30. Ramsey, S. (2005). Economic evaluation of genetic testing technologies, genomics and medicine: How do we facilitate clinical translation of gene-based discoveries? Rockville MD: Agency for Health Care Research and Quality.
31. Russell, L. B., Gold, M. R., Siegel, J. E., Daniels, N., & Weinstein, M. C. (1996). The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA, 276, 1172-1177.
32. Schoen, E. J., Baker, J. C., Colby, C. J., & To, T. T. (2002). Cost-benefit analysis of universal tandem mass spectrometry for newborn screening. Pediatrics, 110, 781-786.
33. Seymour, C. A., Thomason, M. J., Chalmers, R. A., Addison, G. M., Bain, M. D., Cockburn, F., et al. (1997). Newborn screening for inborn errors of metabolism: A systematic review. Health Technology Assessment, 1(11), i-iv, 1-95.
34. Stoddard, J. J., & Farrell, P. M. (1997). State-to-state variations in newborn screening policies. Archives of Pediatrics & Adolescent Medicine, 151, 561-564.
35. Tiwary, C (1987). Proposed guidelines for screening of metabolic and endocrine diseases of dependent neonates of the U.S. Armed Forces. Derived from a survey of state guidelines for neonatal screening of metabolic diseases. Clinical Pediatrics, 26, 349-354.
36. Venditti, L., Venditti, C., Berry, G., Kaplan, P., Kaye, E., Glick, H., et al. (2003). Newborn screening by tandem mass spectrometry for medium-chain Acyl-CoA dehydrogenase deficiency: A cost-effectiveness analysis. Pediatrics, 112, 1005-1015.
37. Watson, M. (2004). Newborn screening: Towards a uniform screening panel and system. Draft Final Report. U.S. Department of Health and Human Services, Washington, DC.
38. Wennberg, J. (2004). Practice variation: Implications for our health care system. Managed Care, 13(9 Suppl.), 3-7.